Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone

Resistance to second-line tuberculosis drugs for patients with multidrug-resistant tuberculosis has emerged globally and is a potential risk factor for unfavorable outcomes of shorter duration drug regimens. We assessed the proportion of patients eligible for a shorter drug regimen in Uttar Pradesh,...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Pravin K., Jain, Amita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2019
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711219/
https://www.ncbi.nlm.nih.gov/pubmed/31441763
http://dx.doi.org/10.3201/eid2509.190105
_version_ 1783446478298021888
author Singh, Pravin K.
Jain, Amita
author_facet Singh, Pravin K.
Jain, Amita
author_sort Singh, Pravin K.
collection PubMed
description Resistance to second-line tuberculosis drugs for patients with multidrug-resistant tuberculosis has emerged globally and is a potential risk factor for unfavorable outcomes of shorter duration drug regimens. We assessed the proportion of patients eligible for a shorter drug regimen in Uttar Pradesh, India, which had the highest rate of multidrug-resistant tuberculosis in India.
format Online
Article
Text
id pubmed-6711219
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-67112192019-09-04 Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone Singh, Pravin K. Jain, Amita Emerg Infect Dis Research Letter Resistance to second-line tuberculosis drugs for patients with multidrug-resistant tuberculosis has emerged globally and is a potential risk factor for unfavorable outcomes of shorter duration drug regimens. We assessed the proportion of patients eligible for a shorter drug regimen in Uttar Pradesh, India, which had the highest rate of multidrug-resistant tuberculosis in India. Centers for Disease Control and Prevention 2019-09 /pmc/articles/PMC6711219/ /pubmed/31441763 http://dx.doi.org/10.3201/eid2509.190105 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Singh, Pravin K.
Jain, Amita
Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title_full Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title_fullStr Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title_full_unstemmed Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title_short Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
title_sort limited scope of shorter drug regimen for mdr tb caused by high resistance to fluoroquinolone
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711219/
https://www.ncbi.nlm.nih.gov/pubmed/31441763
http://dx.doi.org/10.3201/eid2509.190105
work_keys_str_mv AT singhpravink limitedscopeofshorterdrugregimenformdrtbcausedbyhighresistancetofluoroquinolone
AT jainamita limitedscopeofshorterdrugregimenformdrtbcausedbyhighresistancetofluoroquinolone

Ejemplares similares